M
46.10
-0.19 (-0.41%)
| Penutupan Terdahulu | 46.29 |
| Buka | 46.00 |
| Jumlah Dagangan | 459,783 |
| Purata Dagangan (3B) | 634,265 |
| Modal Pasaran | 3,185,071,872 |
| Harga / Jualan (P/S) | 79.29 |
| Harga / Buku (P/B) | 4.76 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 May 2025 - 12 May 2025 |
| Margin Operasi (TTM) | -969.93% |
| EPS Cair (TTM) | -3.35 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 2.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.53% |
| Nisbah Semasa (MRQ) | 6.53 |
| Aliran Tunai Operasi (OCF TTM) | -185.84 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -123.22 M |
| Pulangan Atas Aset (ROA TTM) | -27.47% |
| Pulangan Atas Ekuiti (ROE TTM) | -42.88% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Merus N.V. | Menurun | Menaik |
AISkor Stockmoo
1.3
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.30 |
|
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 2.04% |
| % Dimiliki oleh Institusi | 106.49% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 109.00 (Guggenheim, 136.44%) | Beli |
| Median | 84.00 (82.21%) | |
| Rendah | 70.00 (B of A Securities, 51.84%) | Beli |
| Purata | 86.20 (86.99%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 44.84 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 28 Mar 2025 | 109.00 (136.44%) | Beli | 44.61 |
| 18 Mar 2025 | 109.00 (136.44%) | Beli | 46.39 | |
| B of A Securities | 10 Mar 2025 | 70.00 (51.84%) | Beli | 46.75 |
| HC Wainwright & Co. | 03 Mar 2025 | 85.00 (84.38%) | Beli | 45.47 |
| Needham | 28 Feb 2025 | 83.00 (80.04%) | Beli | 47.09 |
| Piper Sandler | 13 Feb 2025 | 84.00 (82.21%) | Beli | 40.30 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| SHUMAN HARRY | - | 47.24 | -4,000 | -188,960 |
| Jumlah Keseluruhan Kuantiti Bersih | -4,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -188,960 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 47.24 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| SHUMAN HARRY | Pegawai | 21 Mar 2025 | Jual (-) | 4,000 | 47.24 | 188,960 |
| SHUMAN HARRY | Pegawai | 21 Mar 2025 | Pelaksanaan pilihan | 3,000 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |